Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

Background. No established chemotherapeutic regimen exists for the treatment of recurrent malignant gliomas (rMGs). Herein, we report the activity and safety results of the bevacizumab (B) plus fotemustine (FTM) combination for the treatment of rMGs. Patients and Methods. An induction phase consiste...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Vaccaro, V., Fabi, A., Vidiri, A., Giannarelli, D., Metro, G., Telera, S., Vari, S., Piludu, F., Carosi, M. A., Villani, V., Cognetti, F., Pompili, A., Marucci, L., Carapella, C. M., Pace, A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Hindawi Publishing Corporation 2014
Pynciau:
Clinical Study
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4024398/
https://ncbi.nlm.nih.gov/pubmed/24877084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/351252
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg